East Hanover, New Jersey, United States
with other locations globally
At Novartis, we are driven by a single mission: to discover new ways to improve and extend people’s lives. Through science-based innovation we address some of society’s most challenging healthcare issues. Working to discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Novartis focuses on innovative patent-protected medicines, generics and eye care products – segments where we have global reach and strong relations with our customers. Research and development (R&D) sits at the core of our business and central to our strategy. Our global organizations for manufacturing, business services and other functions help increase efficiency and promote excellence.
12 articles with Novartis
Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced its debut as an independent, publicly traded company and the completion of its separation from Novartis.
Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System
Acquisition of IFM Therapeutics subsidiary gives Novartis full rights to one clinical and two pre-clinical NLRP3 antagonist programs
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy
Updated Phase 1 Clinical Trial Monotherapy Data for IDE196 in Metastatic Uveal Melanoma to be Presented at AACR Conference
IDEAYA Biosciences, Inc. announced that Novartis will present a poster with data from an ongoing clinical trial evaluating the tolerability and preliminary clinical activity of IDE196 as a potential monotherapy in metastatic uveal melanoma.
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Mayzent is approved across the MS spectrum for clinically isolated syndrome (CIS), RRMS and active SPMS, with most patients not requiring a first dose observation
Novartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients
Outcomes from PIONEER-HF 4-week open-label extension reinforce initial 8-week findings, showing Entresto® (sacubitril/valsartan) continued to deliver reductions in NT-proBNP, an established biomarker for heart failure severity and prognosis
FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability
Multi-year agreement will provide access to AbCellera’s expertise and state-of-the-art antibody discovery technology for up to ten clinically-relevant disease targets.
Novartis Pharmaceuticals Corporation Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
Novartis Pharmaceuticals Corporation Release: New Data Show Overactive Bladder Therapy Enablex(R) Does Not Impair Memory Function Compared To Frequently Used Alternative